Janux Therapeutics (NASDAQ:JANX) Stock Price Down 4.1%

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report)'s share price traded down 4.1% during mid-day trading on Wednesday . The company traded as low as $48.00 and last traded at $48.46. 288,929 shares changed hands during trading, a decline of 62% from the average session volume of 755,735 shares. The stock had previously closed at $50.55.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. BTIG Research initiated coverage on shares of Janux Therapeutics in a report on Thursday, March 21st. They issued a "buy" rating and a $62.00 price target for the company. Cantor Fitzgerald began coverage on Janux Therapeutics in a research note on Wednesday, March 20th. They issued an "overweight" rating and a $100.00 target price for the company. Wedbush reaffirmed an "outperform" rating and set a $53.00 price target on shares of Janux Therapeutics in a research note on Monday, March 11th. Bank of America raised their price objective on Janux Therapeutics from $24.00 to $48.00 and gave the company a "buy" rating in a research note on Wednesday, March 13th. Finally, Jonestrading began coverage on Janux Therapeutics in a research report on Tuesday. They set a "buy" rating and a $70.00 target price on the stock. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $61.33.

Janux Therapeutics Price Performance

The company's fifty day moving average price is $32.84 and its 200 day moving average price is $17.39. The company has a market cap of $2.48 billion, a PE ratio of -35.51 and a beta of 4.18.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings results on Friday, March 8th. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.12. The company had revenue of $2.46 million during the quarter, compared to the consensus estimate of $0.98 million. Janux Therapeutics had a negative return on equity of 17.88% and a negative net margin of 721.18%. On average, analysts forecast that Janux Therapeutics, Inc. will post -1.41 EPS for the current year.

Institutional Trading of Janux Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC grew its stake in shares of Janux Therapeutics by 10,740.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,710 shares of the company's stock worth $29,000 after acquiring an additional 2,685 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Janux Therapeutics by 149.4% during the first quarter. Tower Research Capital LLC TRC now owns 3,344 shares of the company's stock valued at $40,000 after purchasing an additional 2,003 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Janux Therapeutics during the fourth quarter worth about $57,000. Barclays PLC boosted its position in Janux Therapeutics by 533.0% during the fourth quarter. Barclays PLC now owns 4,608 shares of the company's stock worth $61,000 after purchasing an additional 3,880 shares during the period. Finally, Citigroup Inc. increased its stake in shares of Janux Therapeutics by 935.2% in the second quarter. Citigroup Inc. now owns 5,787 shares of the company's stock worth $69,000 after purchasing an additional 5,228 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company's stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.